The clinical picture in prostate cancer has been dramatically altered by prostate-specific antigen (PSA) testing and by the use of luteinizing hormone-releasing hormone (LHrH) analogues (Tolis et al, 1982; Waxman et al, 1983). Here, KLK3 is linked to prostate cancer.